Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

Inclusion criteria: * Male or female patients 18 years or older. * Have B-precursor, T cell ALL, MPAL or LBL in CR following therapy and receiving maintenance therapy. Patients with persistent minimal residual disease and/or in complete remission with incomplete platelet recovery are not eligible. * Prior therapy: Should have achieved CR following the induction and intensification phases of treatment, with no limit on the number of prior treatment regimens, and started treatment with POMP/D maintenance. Patients who achieved CRp or CR with persistence of minimal residual disease are not eligible. * Patients are eligible after allogeneic stem cell transplantation. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Patients must meet the following clinical laboratory criteria: * Total bilirubin \< 1.5 X the upper limit of the normal range (ULN). * Alanine aminotransferase (ALT) and aspartate aminotransferase. (AST) \< 3 X ULN. * Calculated creatinine clearance \> 30 mL/min. * Absolute neutrophil count (ANC) \> 1,000/cmm and platelets \> 75,000/cmm. * Patient has a life expectancy of at least six months. * Patients must be at least two weeks from major surgery, radiation therapy, participation in other investigational trials and have recovered from clinically significant toxicities of these prior treatments. * Patients should be on stable doses of 6-mercaptopurine, methotrexate, vincristine and prednisone/dexamethasone as part of the POMP/D regimen, …